-
The invention relates to a method for antigen-specific stimulation of T lymphocytes with synthetic peptide libraries, comprising the following steps: [0001]
-
(a) subdividing the total amino acid sequence of the antigen into protein fragments with partial amino acid sequences; [0002]
-
(b) synthesizing a peptide library containing these protein fragments; [0003]
-
(c) incubating a suspension containing CD8+ and/or CD4+ T lymphocytes with all the protein fragments of the peptide library in a single culture run. [0004]
-
The method can be employed for both the immunostimulation of T lymphocytes of mammals, especially humans, and for diagnostics in order to establish whether a mammal, especially a human, has previously responded to a specific protein with its immune system, and if so, how strong such response is. [0005]
BACKGROUND OF THE INVENTION
-
The immune response of CD8+ T lymphocytes to protein antigens can be detected only with a great expenditure using known methods. It depends on the presentation of the epitopes derived from these antigens on MHC class I molecules on cells and can be measured through measuring a cytotoxic response induced by exposure. This experimental set-up is usual and takes one to several weeks in which the CD8+ T lymphocytes must be stimulated with the antigen in a suitable cell culture and are then incubated in a cytotoxicity test with suitable target cells which have been loaded with peptides from this antigen or transfected with the antigen or parts thereof. The induction of a response of the CD8+ T lymphocytes is measured from the degree of destruction of target cells, which requires suitable controls and includes a great experimental and time expenditure. [0006]
-
The detection of the immune response of CD4+ T lymphocytes to protein antigens is somewhat less complicated. The response of CD4+ T lymphocytes to protein antigens depends on the presentation of the epitopes derived from these antigens on MHC class II molecules on cells and can be measured through the proliferation of such cells in the presence of the antigen or upon exposure to this antigen, e.g., through the incorporation of tritiated thymidine. This experimental set-up is usual and takes several days up to a week or longer. The presence of a CD4+ T lymphocyte response to protein antigens can further be measured in a known method in which a suspension containing CD4+ T lymphocytes is incubated with the corresponding protein followed by detecting the CD4+ T lymphocyte induction through the presence of intracellular cytokines by flow cytometry. [0007]
-
The presence of a CD8+ T lymphocyte or CD4+ T lymphocyte response to individual epitopes can further be measured in a known method in which a suspension containing CD8+ and/or CD4+ T lymphocytes is incubated with peptides from this protein followed by detecting the CD8+ or CD4+ T lymphocyte induction through the presence of intracellular cytokines by flow cytometry, making use of the fact that peptides can be charged directly from outside onto the MHC class I or MHC class II molecules on cells, circumventing intracellular processing. In this method, it can be achieved by a suitable grouping of peptides that stimulating peptides can be identified and thus epitopes can be determined. The grouping used in this way distributes all possible epitopes to several, and mostly a large number of, runs so that it can be established whether individual peptides from this protein can induce a T lymphocyte response and it can be established which of the peptides occurring in the individual groups have led to such stimulation (this is described in F. Kern et al., Journal of Virology, October 1999, p. 8179-8184, and in [0008] WO 99/36568).
-
However, this grouping allows neither to determine systematically in a single measurement with a corresponding control whether a T lymphocyte response against the protein is present at all, nor to tell how strong the response (the proportion of the reactive lymphocytes in percent of the total CD8+ or CD4+ T lymphocytes) to this protein is all in all. To do this, the usual grouping in this method for the identification of epitopes would require several stimulation and measuring runs, depending on the number of peptides used. The application described in the literature aims at the precise identification of epitopes and therefore uses groups of peptides whose size is chosen in such a way that as few as possible individual peptides must be tested to establish the stimulating activity of a peptide group. However, the smaller the group size is chosen, the more groups have to be tested. Therefore, as the most favorable variant, a number of groups is chosen in this method which is twice the square root of the next square number exceeding the number of the peptides (unless the number of peptides is itself a square number). [0009]
-
This may be exemplified by the pp65 protein of the human cytomegalovirus. 138 peptides were synthesized which cover the amino acid sequence of the whole protein (561 amino acids) to the full length thereof, neighboring peptides overlapping by 9 amino acids each. 138 is not a square number. The next higher square number from 138 is 144 (12×12). Thus, the peptides were distributed to 2×12, i.e. 24, groups in such a way that each peptide occurs in exactly two different groups. By combining the groups with positive results (stimulation), the stimulating peptide can be concluded directly (when only two groups show a positive result), or it can be narrowed down to a small number of candidate peptides which can be retested individually, if more then two groups of peptides have resulted in positive stimulation results. The principle of this grouping has been described in some detail by F. Kern et al., Journal of Virology, October 1999, p. 8179-8184. A possibility for telling by one single run with a corresponding negative control whether a protein has a stimulating effect on CD8+ T lymphocytes, i.e., whether the amino acid sequence of this protein contains epitopes which are recognized by CD8+ T lymphocytes, has not been described to date. [0010]
DESCRIPTION OF THE INVENTION
-
The object of the invention is to provide a possibility for how to employ protein antigens of known sequence for the immunostimulation of CD8+ and CD4+ T lymphocytes, wherein cellular antigen processing is not necessary and individual antigenic determinants (epitopes) need not be identified. It has now been found that a sufficient immunostimulation can be achieved by incubation with T lymphocytes of a special peptide library of individual fragments of the antigen with some overlapping of the fragments. The stimulation can be detected by flow cytometry. Thus, it can be established whether an organism (human or animal) has built up a T lymphocyte response against the immunizing antigen after an exposure which has occurred (also well-aimed immunization). This T lymphocyte reactivity can be examined in terms of its time course. A further object of the invention is to provide a method by which protein antigens whose amino acid sequences are known can be identified as T-lymphocyte-stimulating protein antigens within a short time and with comparably few expenditure. This further provides a possibility for examining prior to the selection of a protein for the identification of epitopes whether T-lymphocyte-stimulating antigenic determinants are at all present in this protein. [0011]
-
Thus, the present invention relates to [0012]
-
(1) a method for the antigen-specific stimulation of T lymphocytes with synthetic peptide libraries, comprising the following steps: [0013]
-
(a) subdividing the total amino acid sequence of the antigen into protein fragments with partial amino acid sequences, wherein said protein fragments have a minimum length of 9 amino acid residues (also briefly referred to as “AA” in the following), and wherein adjacent or neighboring protein fragments are overlapping with their partial amino acid sequence; [0014]
-
(b) synthesizing a peptide library containing the protein fragments defined in (a); [0015]
-
(c) incubating a suspension containing CD8+ and/or CD4+ T lymphocytes with all the protein fragments of the peptide library obtained in (b) in a single culture run; [0016]
-
(2) in a preferred embodiment of method (1), it is adapted for in-vivo and in-vitro immunostimulation of T lymphocytes of mammals, especially humans; [0017]
-
(3) stimulated T lymphocytes obtainable by the method as defined above under (2); [0018]
-
(4) use of a peptide library as defined above under (1) for the preparation of a medicament for in-vivo immunostimulation of T lymphocytes of mammals; and [0019]
-
(5) a composition for in-vitro and in-vivo immunostimulation of T lymphocytes of mammals, comprising one or more peptide libraries as defined above under (1).[0020]
DESCRIPTION OF FIGURES
-
FIG. 1: Peptides for whole pool HCMV IE-1 (laboratory strain AD169). The sequence of the starting protein, VIE1-[0021] HCMVA 55 kDa immediate-early protein 1 (IE1), human cytomegalovirus (strain AD169), is known from Swiss-Prot P13202 and depicted in SEQ ID NO:1.
-
FIG. 2: Peptides for whole pool HCMV pp65 (laboratory strain AD169). The sequence of the starting protein, PP65-[0022] HCMVA 65 kDa lower matrix phosphoprotein (pp65), human cytomegalovirus (strain AD169), is known from Swiss-Prot P06725 and depicted in SEQ ID NO:2.
-
FIG. 3: Detection of intracellular interferon-gamma in CD8+ T lymphocytes upon stimulation with the peptide libraries described. The marker CD69 was used as an activation marker in addition to interferon-gamma. The representation has been limited to CD3+/CD8+ events, stating the average fluorescence intensity. [0023]
DETAILED DESCRIPTION OF THE INVENTION
-
“Antigens” in the method according to the invention are those antigens which have a peptide basic structure (i.e., proteins, parts of proteins or polypeptides etc.). The antigen in step (a) of the above defined method is an antigen (i.e., protein, part of a protein, or polypeptide) to which a T lymphocyte stimulation is desired, or on which it is to be tested whether such a stimulation has already occurred. [0024]
-
“Proteins or peptides” in the present invention have a sequence of at least nine AAs as an essential feature. [0025]
-
A “peptide library” within the meaning of the application is a complex mixture of peptides which in their entirety cover the complete sequence of a protein antigen or partial antigen, which is in such a way that successive peptides are overlapping along this sequence. [0026]
-
Therefore, in the method according to embodiment (1) of the invention, it may be necessary to determine the total amino acid sequence of the antigen prior to the above mentioned step (a), especially when the amino acid sequence of the antigen is not known. [0027]
-
It does not matter how the sequence of the antigen has been established. Thus, for a new protein, the sequence can be analyzed for the first time, or for a known protein, it may be read from a data base. It is only important that the amino acid sequence of the protein or partial protein has been determined. [0028]
-
In a preferred embodiment of method (1) according to the invention, the protein fragments have a minimum length of 15 AAs and/or a maximum length of 35 AAs, preferably 25 AAs. It is further preferred that an overlap of 8 AAs, preferably 11 AAs, is present between neighboring protein fragments. In addition, the synthetic protein fragments may be extended by a maximum of 7 natural or artificial AAs and/or a protective group at either or both of their N terminus and C terminus. These extensions of natural or artificial AAs are non-overlapping sequences. [0029]
-
Suitable protective groups on the N terminus of the protein fragments are alkyl, aryl, alkylaryl, aralkyl, alkylcarbonyl or arylcarbonyl, having from 1 to 10 carbon atoms, an acyl group having from 1 to 7 carbon atoms, etc. Preferred protective groups for the N terminus are the naphthoyl, naphthylacetyl, naphthylpropionyl and benzoyl groups. Suitable protective groups for the C terminus of the protein fragments are alkoxy or aryloxy groups having from 1 to 10 carbon atoms or an amino group. Further protective groups are described in Houben-Weyl (1974), Georg Thieme Verlag, 4th Edition. The description of the protective groups in the above reference is included herein by reference. [0030]
-
Further, it is preferred that the concentration of the individual protein fragments of the peptide library is at least 1 ng/ml, preferably from about 0.1 to about 10 μg/ml in the culture run (final concentration). Particularly preferred is a concentration of about 1 μg/ml of culture broth. [0031]
-
In addition, it is preferred that the incubation solution (i.e., the culture broth) further contains one or more compounds having costimulatory properties, such as costimulatory antibodies (e.g. anti-CD28 or anti-CD49d) or other molecules having costimulatory properties. (e.g., stimulatory CTLA4-Ig). These compounds are preferably contained in the culture broth in final concentration of from 0.1 to 10 μg/ml. [0032]
-
A particularly preferred embodiment of the method (1) according to the invention for the antigen-specific stimulation of T lymphocytes with synthetic peptide libraries comprises the following steps: [0033]
-
(a[0034] 1) determining the total amino acid sequence of the antigen, which is a protein or part of a protein;
-
(a[0035] 2) subdividing the total amino acid sequence in protein fragments having partial amino acid sequences, wherein the protein fragments have a minimum length of 9 (preferably 15) AAs, optionally have a maximum length of 25 AAs, and wherein adjacent or neighboring protein fragments are over-lapping with their partial amino acid sequence, an overlap of 8 AAs, especially an overlap of 11 AAs, being preferred;
-
(b) synthesizing a peptide library containing the protein fragments defined in (a2), optionally extended by a maximum of 7 natural or artificial amino acids and/or a protective group at either or both of the N terminus and C terminus; [0036]
-
(c) incubating a suspension containing CD8+ and/or CD4+ T lymphocytes with all the protein fragments of the peptide library in a single culture run. [0037]
-
Preferred is the use of the method according to the invention for identifying stimulating or non-stimulating mixtures of all protein fragments in a single culture run, wherein the following steps are added: [0038]
-
(d) identifying (preferably flow-cytometric identifying) of [0039]
-
(i) at least one T-cell cytokine which was induced by the protein fragment or fragments and synthesized in the T lymphocytes, wherein said cytokine or cytokines are intracellular or bound to the cell membrane; and/or [0040]
-
(ii) at least one activation marker which was induced by the protein fragment or fragments and synthesized in the T lymphocytes, wherein said activation marker or markers are intracellular or bound to the cell membrane. [0041]
-
The method (1) according to the invention is also suitable for establishing whether T-lymphocyte-stimulating antigenic determinants are present in an antigen. [0042]
-
The method according to the invention is further suitable for diagnostics, especially to establish whether a mammal, especially a human, has previously responded to a specific protein with its immune system, and how strong such response is. [0043]
-
According to the preferred embodiment (2) of the invention, the method is suitable for immunostimulation of T lymphocytes of mammals, especially humans, for both in-vitro and in-vivo applications. This method may further include the expanding of the stimulated T lymphocytes. [0044]
-
The above mentioned embodiments of the method according to the invention may also be designed to employ several different synthetic peptide libraries (from different antigens) together in one culture run or in separated culture runs. [0045]
-
Suspensions containing T lymphocytes within the meaning of this application are characterized by containing cells which can present MHC-bound peptides. Thus, the presenting cells may also be T lymphocytes in addition to the antigen-presenting cells. [0046]
-
An advantage of the method according to the invention is the fact that the identification of at least one T-cell cytokine or activation marker is effected on the level of the individual cell. Thus, it is possible to exactly determine the phenotype of the responding cells. Cytokines and surface markers are described in some detail in Abul K. Abbas et al. (1997), Cellular and Molecular Immunology, Philadelphia, 3rd Edition, ISBN 0-7216-4024-9. [0047]
-
It is known that protein fragments binding to MHC class I molecules (MHC=major histocompatibility complex) usually have a length of 9 amino acids, while protein fragments binding to MHC class II molecules are somewhat longer and more variable in length. [0048]
-
An advantage of methods (1) and (2) according to the invention is the fact that, despite of the short incubation time, the protein fragments are taken up by the MHC molecules present on the cell surface sufficiently to enable an unambiguous identification of a T-cell stimulation after six hours, for example. [0049]
-
In the method according to the invention, the suspension containing T lymphocytes can be derived from whole blood, peripheral white blood cells (PWBC), splenocytes, thymocytes, bone marrow, cerebrospinal fluid, lymph node cells, etc. [0050]
-
In the method according to the invention, it is particularly advantageous that processing of the T lymphocytes is not required. Thus, the T lymphocytes need not be enriched, and further, the removal or destruction of other cells is not necessary. Thus, the method according to the invention can be practiced more simply in a routine manner. [0051]
-
Preferred is a method according to the invention for antigen-specific stimulation of T lymphocytes with synthetic peptide libraries in which the suspension containing the T lymphocytes is derived from patients to be treated, from other donors or from animals. If the suspension containing T lymphocytes is derived from a patient, the identification can be used, for example, for establishing to which protein of a virus a CD8+ or CD4+ T lymphocyte response can be induced. The peptide library employed for examining this reactivity can then be selectively employed for the stimulation of further T lymphocytes of the same or other patients. The cells thus induced and stimulated for proliferation can be expanded in vivo or ex vivo and subsequently retransfused to the patient. [0052]
-
The method according to the invention can also be used in veterinary medicine. It is possible to use a wide variety of animal species and also constellations of animal patients and donors as the source of the suspension containing T lymphocytes. [0053]
-
Advantageous is a method according to the invention for the antigen-specific stimulation of T lymphocytes with synthetic peptide libraries in which the antigens, which are proteins or partial proteins, are derived from microorganisms, macroorganisms, cells, cell cultures and/or tissues from donors or patients. Microorganisms include, for example, viruses, bacteria, fungi, protozoans, parasites. Macroorganisms include, for example, all multicellular eukaryotes. This source is just important for influencing allergies. Included are animals and plants. There may be used cells, cell cultures or even whole tissues consisting of one or more layers or cell types. [0054]
-
Preferred is a method according to the invention for antigen-specific stimulation of T lymphocytes with synthetic peptide libraries in which the stimulation is detected by means of a flow cytometer. What is essential is the principle that markers present in the cell or on its surface, such as cytokines or surface markers, will contact with a specific detector, for example, an antibody, the detector being loaded with a fluorescent dye. Upon excitation by laser light of this fluorescent dye on the cells focused in a liquid stream, the flow cytometer records the emitted scattered light and fluorescence signals, which enables the simultaneous or later analysis of the cells. Such techniques are described in some detail in Howard M. Shapiro (1995), Practical Flow Cytometry, New York, 3rd Edition, ISBN 0-471-30376-3. The detection of the intracellular cytokines is described in ILL. Picker et al. (1995), Blood, Vol. 86, p. 1408. [0055]
-
The advantage of this method according to the invention for antigen-specific stimulation of T lymphocytes with synthetic peptide libraries is that a reagent for the immunostimulation of T lymphocytes can be made available within a very short period of time and, as compared to the conventional method, with very low expenditure. It is further advantageous that individual stimulating epitopes need not to be identified. [0056]
-
In a single run (one tube or one well or one flask, etc.), the T lymphocytes of a donor/patient (CD8 and/or CD4) can be stimulated simultaneously with all possible antigenic determinants of the protein (or proteins when several peptide libraries are used) without needing to be specifically known. For example, the T lymphocytes of a patient who has undergone a bone marrow transplantation could be incubated with HLA-identical dendritic cells which were previously incubated with such a mixture of peptides, and thus these T lymphocytes could be stimulated with all epitopes relevant (i.e., binding) to the particular HLA type without these epitopes needing to be known or becoming known by the method. The only critical point is that they stimulate T lymphocytes and belong to the selected protein or proteins. These cells could be retransferred to the patient within the scope of an adoptive immunotherapy. [0057]
-
A preferred source of the T lymphocytes to be stimulated are those (human or animal) donors which have previously build up an immunological primary response to the antigen or in which such an immune response to the antigen has been induced by exposure. This may have occurred, for example, within the scope of an infection or also within the scope of an immunization. This situation also prevails in an auto-immune response. [0058]
-
Another advantage is that the MHC type of the donor need not be known. A further advantage is that the stimulation of both CD8+ and CD4+ T lymphocytes can be examined simultaneously and in a single run. [0059]
-
The stimulated T lymphocytes according to embodiment (3) of the invention are preferably obtained by in-vitro stimulation. The stimulated lymphocytes are capable of being transfused into a patient. [0060]
-
The medicament according to embodiment (4) of the invention may contain further immunoreactive compounds, such as the above defined compounds having co-stimulating properties, in addition to usual additives and auxiliaries. The medicament may also contain several of the above defined peptide libraries. [0061]
-
The composition according to embodiment (5) can be a pharmaceutical composition, i.e., for the in-vivo treatment of humans and animals, or a diagnostic composition or a so-called kit, i.e., primary for in-vitro application, wherein the peptide library is respectively adapted to the antigen to be stimulated. As to further components of the composition, the same applies as has been set forth above with respect to embodiment (4). [0062]
-
The present invention is further illustrated by the following non-limiting Example. [0063]
EXAMPLE
-
Mononuclear cells were prepared from the peripheral blood of two patients obtained by venous puncture. The patients possessed antibodies against the human cytomegalovirus (HCMV). The cells prepared by standard methods were incubated for six hours under optimized conditions with peptide libraries for the [0064] HCMV proteins 65 kD lower matrix phosphoprotein (pp65) and 55 kDa immediate-early protein 1 (IE1). This is done according to the method described in Kern et al., Eur. J. Immunol. 30: 1676-1682 (2000), which comprises the following steps:
-
1. Resuspension of PBMC (2.5×10[0065] 6/ml in RPMI 1640 with 2 mM glutamine added) after Ficoll preparation (standard protocol).
-
2. 400 μl of this suspension was mixed in an incubation vessel (sterile tube from Falcon No. 2054, 5 ml) with 100 μl of peptide solution (containing 10 μg of each individual peptide in RPMI 1640 with 2 mM glutamine added). [0066]
-
3. Incubation at 37° C. under an H[0067] 2O-saturated atmosphere with 5% CO2 (standard incubator).
-
4. After 2 hours, there was added 500 μl of RPMI 1640 to which 20% fetal calf serum (v/v) and additionally glutamine (2 mM) and 10 μg of Brefeldin A (BFA, final concentration in the mix was 10 μg/ml) had been added. The final concentration of fetal calf serum in the mix is 10% (v/v). The final concentration of each individual peptide is 1 μg/ml. BFA serves to retain synthetic cytokines in the cells, which is of advantage for the detection of the intracellular cytokines. The final volume of the mix is 1 ml. [0068]
-
5. After further incubation for 4 h under the same conditions (i.e., a total incubation time of 6 h), the incubation was stopped by adding ice-cold PBS buffer solution. [0069]
-
6. This was followed by centrifugation (8 min, 400 g), decantation and further processing of the samples according to a standard protocol, including detachment from the tube wall using 2 mM EDTA/PBS solution, fixation, permeabilization and staining with monoclonal antibodies. [0070]
-
7. Analysis on a flow cytometer (e.g., a four-color fluorescence flow cytometer of the type FacsCalibur (Becton Dickinson)). [0071]
-
The sequences of IE-1 and pp65 have been deposited in the SWISS-PROT data base, European Bioinformatics Institute, under the Nos. P13202 (see also SEQ ID NO: 1) and P06725 (see also SEQ ID NO: 2). In addition, the sequences of both proteins are described in M. S. Chee, A. T. Bankier, S. Becks et al., Curr. Top. Microbiol. Immunol. 154: 125-169 (1990). [0072]
-
The peptide library which represents the 55 kD immediate-[0073] early protein 1 consisted of peptides of 15 amino acids length each with 9 overlaps between successive peptides (see FIG. 1), and the peptide library which represents the 65 kD lower matrix phosphoprotein consisted of peptides of 15 amino acids length each with 11 overlaps between successive peptides (see FIG. 2).
-
In two different individuals (coluumns “I)” and “II)” in FIG. 3), incubation with the peptide libraries resulted in the production of IFN-gamma in T cells, which was detected by measurement on a flow cytometer on the level of the individual cells (J. L. Picker et al. (1995), Blood, Vol. 86, p. 1408-1419), or else in no detectable stimulation. Individual I exhibited a CD8+ T lymphocyte response to IE-1, but not to pp65, whereas individual II exhibited a CD8+ T lymphocyte response to both proteins. Incubation with an irrelevant peptide did not produce this effect (control). [0074]
-
1
260
1
491
PRT
Artificial Sequence
Description of Artificial Sequence HCMV IE-1
1
Met Glu Ser Ser Ala Lys Arg Lys Met Asp Pro Asp Asn Pro Asp Glu
1 5 10 15
Gly Pro Ser Ser Lys Val Pro Arg Pro Glu Thr Pro Val Thr Lys Ala
20 25 30
Thr Thr Phe Leu Gln Thr Met Leu Arg Lys Glu Val Asn Ser Gln Leu
35 40 45
Ser Leu Gly Asp Pro Leu Phe Pro Glu Leu Ala Glu Glu Ser Leu Lys
50 55 60
Thr Phe Glu Gln Val Thr Glu Asp Cys Asn Glu Asn Pro Glu Lys Asp
65 70 75 80
Val Leu Ala Glu Leu Val Lys Gln Ile Lys Val Arg Val Asp Met Val
85 90 95
Arg His Arg Ile Lys Glu His Met Leu Lys Lys Tyr Thr Gln Thr Glu
100 105 110
Glu Lys Phe Thr Gly Ala Phe Asn Met Met Gly Gly Cys Leu Gln Asn
115 120 125
Ala Leu Asp Ile Leu Asp Lys Val His Glu Pro Phe Glu Glu Met Lys
130 135 140
Cys Ile Gly Leu Thr Met Gln Ser Met Tyr Glu Asn Tyr Ile Val Pro
145 150 155 160
Glu Asp Lys Arg Glu Met Trp Met Ala Cys Ile Lys Glu Leu His Asp
165 170 175
Val Ser Lys Gly Ala Ala Asn Lys Leu Gly Gly Ala Leu Gln Ala Lys
180 185 190
Ala Arg Ala Lys Lys Asp Glu Leu Arg Arg Lys Met Met Tyr Met Cys
195 200 205
Tyr Arg Asn Ile Glu Phe Phe Thr Lys Asn Ser Ala Phe Pro Lys Thr
210 215 220
Thr Asn Gly Cys Ser Gln Ala Met Ala Ala Leu Gln Asn Leu Pro Gln
225 230 235 240
Cys Ser Pro Asp Glu Ile Met Ala Tyr Ala Gln Lys Ile Phe Lys Ile
245 250 255
Leu Asp Glu Glu Arg Asp Lys Val Leu Thr His Ile Asp His Ile Phe
260 265 270
Met Asp Ile Leu Thr Thr Cys Val Glu Thr Met Cys Asn Glu Tyr Lys
275 280 285
Val Thr Ser Asp Ala Cys Met Met Thr Met Tyr Gly Gly Ile Ser Leu
290 295 300
Leu Ser Glu Phe Cys Arg Val Leu Cys Cys Tyr Val Leu Glu Glu Thr
305 310 315 320
Ser Val Met Leu Ala Lys Arg Pro Leu Ile Thr Lys Pro Glu Val Ile
325 330 335
Ser Val Met Lys Arg Arg Ile Glu Glu Ile Cys Met Lys Val Phe Ala
340 345 350
Gln Tyr Ile Leu Gly Ala Asp Pro Leu Arg Val Cys Ser Pro Ser Val
355 360 365
Asp Asp Leu Arg Ala Ile Ala Glu Glu Ser Asp Glu Glu Glu Ala Ile
370 375 380
Val Ala Tyr Thr Leu Ala Thr Ala Gly Val Ser Ser Ser Asp Ser Leu
385 390 395 400
Val Ser Pro Pro Glu Ser Pro Val Pro Ala Thr Ile Pro Leu Ser Ser
405 410 415
Val Ile Val Ala Glu Asn Ser Asp Gln Glu Glu Ser Glu Gln Ser Asp
420 425 430
Glu Glu Glu Glu Glu Gly Ala Gln Glu Glu Arg Glu Asp Thr Val Ser
435 440 445
Val Lys Ser Glu Pro Val Ser Glu Ile Glu Glu Val Ala Pro Glu Glu
450 455 460
Glu Glu Asp Gly Ala Glu Glu Pro Thr Ala Ser Gly Gly Lys Ser Thr
465 470 475 480
His Pro Met Val Thr Arg Ser Lys Ala Asp Gln
485 490
2
561
PRT
Artificial Sequence
Description of Artificial Sequence HCMV pp65
2
Met Glu Ser Arg Gly Arg Arg Cys Pro Glu Met Ile Ser Val Leu Gly
1 5 10 15
Pro Ile Ser Gly His Val Leu Lys Ala Val Phe Ser Arg Gly Asp Thr
20 25 30
Pro Val Leu Pro His Glu Thr Arg Leu Leu Gln Thr Gly Ile His Val
35 40 45
Arg Val Ser Gln Pro Ser Leu Ile Leu Val Ser Gln Tyr Thr Pro Asp
50 55 60
Ser Thr Pro Cys His Arg Gly Asp Asn Gln Leu Gln Val Gln His Thr
65 70 75 80
Tyr Phe Thr Gly Ser Glu Val Glu Asn Val Ser Val Asn Val His Asn
85 90 95
Pro Thr Gly Arg Ser Ile Cys Pro Ser Gln Glu Pro Met Ser Ile Tyr
100 105 110
Val Tyr Ala Leu Pro Leu Lys Met Leu Asn Ile Pro Ser Ile Asn Val
115 120 125
His His Tyr Pro Ser Ala Ala Glu Arg Lys His Arg His Leu Pro Val
130 135 140
Ala Asp Ala Val Ile His Ala Ser Gly Lys Gln Met Trp Gln Ala Arg
145 150 155 160
Leu Thr Val Ser Gly Leu Ala Trp Thr Arg Gln Gln Asn Gln Trp Lys
165 170 175
Glu Pro Asp Val Tyr Tyr Thr Ser Ala Phe Val Phe Pro Thr Lys Asp
180 185 190
Val Ala Leu Arg His Val Val Cys Ala His Glu Leu Val Cys Ser Met
195 200 205
Glu Asn Thr Arg Ala Thr Lys Met Gln Val Ile Gly Asp Gln Tyr Val
210 215 220
Lys Val Tyr Leu Glu Ser Phe Cys Glu Asp Val Pro Ser Gly Lys Leu
225 230 235 240
Phe Met His Val Thr Leu Gly Ser Asp Val Glu Glu Asp Leu Thr Met
245 250 255
Thr Arg Asn Pro Gln Pro Phe Met Arg Pro His Glu Arg Asn Gly Phe
260 265 270
Thr Val Leu Cys Pro Lys Asn Met Ile Ile Lys Pro Gly Lys Ile Ser
275 280 285
His Ile Met Leu Asp Val Ala Phe Thr Ser His Glu His Phe Gly Leu
290 295 300
Leu Cys Pro Lys Ser Ile Pro Gly Leu Ser Ile Ser Gly Asn Leu Leu
305 310 315 320
Met Asn Gly Gln Gln Ile Phe Leu Glu Val Gln Ala Ile Arg Glu Thr
325 330 335
Val Glu Leu Arg Gln Tyr Asp Pro Val Ala Ala Leu Phe Phe Phe Asp
340 345 350
Ile Asp Leu Leu Leu Gln Arg Gly Pro Gln Tyr Ser Glu His Pro Thr
355 360 365
Phe Thr Ser Gln Tyr Arg Ile Gln Gly Lys Leu Glu Tyr Arg His Thr
370 375 380
Trp Asp Arg His Asp Glu Gly Ala Ala Gln Gly Asp Asp Asp Val Trp
385 390 395 400
Thr Ser Gly Ser Asp Ser Asp Glu Glu Leu Val Thr Thr Glu Arg Lys
405 410 415
Thr Pro Arg Val Thr Gly Gly Gly Ala Met Ala Gly Ala Ser Thr Ser
420 425 430
Ala Gly Arg Lys Arg Lys Ser Ala Ser Ser Ala Thr Ala Cys Thr Ser
435 440 445
Gly Val Met Thr Arg Gly Arg Leu Lys Ala Glu Ser Thr Val Ala Pro
450 455 460
Glu Glu Asp Thr Asp Glu Asp Ser Asp Asn Glu Ile His Asn Pro Ala
465 470 475 480
Val Phe Thr Trp Pro Pro Trp Gln Ala Gly Ile Leu Ala Arg Asn Leu
485 490 495
Val Pro Met Val Ala Thr Val Gln Gly Gln Asn Leu Lys Tyr Gln Glu
500 505 510
Phe Phe Trp Asp Ala Asn Asp Ile Tyr Arg Ile Phe Ala Glu Leu Glu
515 520 525
Gly Val Trp Gln Pro Ala Ala Gln Pro Lys Arg Arg Arg His Arg Gln
530 535 540
Asp Ala Leu Pro Gly Pro Cys Ile Ala Ser Thr Pro Lys Lys His Arg
545 550 555 560
Gly
3
15
PRT
Artificial Sequence
Description of Artificial Sequence HCMV IE-1
Fragment
3
Met Glu Ser Ser Ala Lys Arg Lys Met Asp Pro Asp Asn Pro Asp
1 5 10 15
4
15
PRT
Artificial Sequence
Description of Artificial Sequence HCMV IE-1
Fragment
4
Gln Thr Met Leu Arg Lys Glu Val Asn Ser Gln Leu Ser Leu Gly
1 5 10 15
5
15
PRT
Artificial Sequence
Description of Artificial Sequence HCMV IE-1
Fragment
5
Ser Asp Ser Leu Val Ser Pro Pro Glu Ser Pro Val Pro Ala Thr
1 5 10 15
6
15
PRT
Artificial Sequence
Description of Artificial Sequence HCMV IE-1
Fragment
6
Val Ser Pro Pro Glu Ser Pro Val Pro Ala Thr Ile Pro Leu Ser
1 5 10 15
7
15
PRT
Artificial Sequence
Description of Artificial Sequence HCMV IE-1
Fragment
7
Glu Ser Pro Val Pro Ala Thr Ile Pro Leu Ser Ser Val Ile Val
1 5 10 15
8
15
PRT
Artificial Sequence
Description of Artificial Sequence HCMV IE-1
Fragment
8
Pro Ala Thr Ile Pro Leu Ser Ser Val Ile Val Ala Glu Asn Ser
1 5 10 15
9
15
PRT
Artificial Sequence
Description of Artificial Sequence HCMV IE-1
Fragment
9
Pro Leu Ser Ser Val Ile Val Ala Glu Asn Ser Asp Gln Glu Glu
1 5 10 15
10
15
PRT
Artificial Sequence
Description of Artificial Sequence HCMV IE-1
Fragment
10
Val Ile Val Ala Glu Asn Ser Asp Gln Glu Glu Ser Glu Gln Ser
1 5 10 15
11
15
PRT
Artificial Sequence
Description of Artificial Sequence HCMV IE-1
Fragment
11
Glu Asn Ser Asp Gln Glu Glu Ser Glu Gln Ser Asp Glu Glu Glu
1 5 10 15
12
15
PRT
Artificial Sequence
Description of Artificial Sequence HCMV IE-1
Fragment
12
Gln Glu Glu Ser Glu Gln Ser Asp Glu Glu Glu Glu Glu Gly Ala
1 5 10 15
13
15
PRT
Artificial Sequence
Description of Artificial Sequence HCMV IE-1
Fragment
13
Glu Gln Ser Asp Glu Glu Glu Glu Glu Gly Ala Gln Glu Glu Arg
1 5 10 15
14
15
PRT
Artificial Sequence
Description of Artificial Sequence HCMV IE-1
Fragment
14
Glu Glu Glu Glu Glu Gly Ala Gln Glu Glu Arg Glu Asp Thr Val
1 5 10 15
15
15
PRT
Artificial Sequence
Description of Artificial Sequence HCMV IE-1
Fragment
15
Arg Lys Glu Val Asn Ser Gln Leu Ser Leu Gly Asp Pro Leu Phe
1 5 10 15
16
15
PRT
Artificial Sequence
Description of Artificial Sequence HCMV IE-1
Fragment
16
Glu Gly Ala Gln Glu Glu Arg Glu Asp Thr Val Ser Val Lys Ser
1 5 10 15
17
15
PRT
Artificial Sequence
Description of Artificial Sequence HCMV IE-1
Fragment
17
Asn Ser Gln Leu Ser Leu Gly Asp Pro Leu Phe Pro Glu Leu Ala
1 5 10 15
18
15
PRT
Artificial Sequence
Description of Artificial Sequence HCMV IE-1
Fragment
18
Ser Leu Gly Asp Pro Leu Phe Pro Glu Leu Ala Glu Glu Ser Leu
1 5 10 15
19
15
PRT
Artificial Sequence
Description of Artificial Sequence HCMV IE-1
Fragment
19
Pro Leu Phe Pro Glu Leu Ala Glu Glu Ser Leu Lys Thr Phe Glu
1 5 10 15
20
15
PRT
Artificial Sequence
Description of Artificial Sequence HCMV IE-1
Fragment
20
Glu Leu Ala Glu Glu Ser Leu Lys Thr Phe Glu Gln Val Thr Glu
1 5 10 15
21
15
PRT
Artificial Sequence
Description of Artificial Sequence HCMV IE-1
Fragment
21
Glu Ser Leu Lys Thr Phe Glu Gln Val Thr Glu Asp Cys Asn Glu
1 5 10 15
22
15
PRT
Artificial Sequence
Description of Artificial Sequence HCMV IE-1
Fragment
22
Thr Phe Glu Gln Val Thr Glu Asp Cys Asn Glu Asn Pro Glu Lys
1 5 10 15
23
15
PRT
Artificial Sequence
Description of Artificial Sequence HCMV IE-1
Fragment
23
Val Thr Glu Asp Cys Asn Glu Asn Pro Glu Lys Asp Val Leu Ala
1 5 10 15
24
15
PRT
Artificial Sequence
Description of Artificial Sequence HCMV IE-1
Fragment
24
Cys Asn Glu Asn Pro Glu Lys Asp Val Leu Ala Glu Leu Val Lys
1 5 10 15
25
15
PRT
Artificial Sequence
Description of Artificial Sequence HCMV IE-1
Fragment
25
Ala Lys Arg Lys Met Asp Pro Asp Asn Pro Asp Glu Gly Pro Ser
1 5 10 15
26
15
PRT
Artificial Sequence
Description of Artificial Sequence HCMV IE-1
Fragment
26
Pro Glu Lys Asp Val Leu Ala Glu Leu Val Lys Gln Ile Lys Val
1 5 10 15
27
15
PRT
Artificial Sequence
Description of Artificial Sequence HCMV IE-1
Fragment
27
Val Leu Ala Glu Leu Val Lys Gln Ile Lys Val Arg Val Asp Met
1 5 10 15
28
15
PRT
Artificial Sequence
Description of Artificial Sequence HCMV IE-1
Fragment
28
Leu Val Lys Gln Ile Lys Val Arg Val Asp Met Val Arg His Arg
1 5 10 15
29
15
PRT
Artificial Sequence
Description of Artificial Sequence HCMV IE-1
Fragment
29
Ile Lys Val Arg Val Asp Met Val Arg His Arg Ile Lys Glu His
1 5 10 15
30
15
PRT
Artificial Sequence
Description of Artificial Sequence HCMV IE-1
Fragment
30
Val Asp Met Val Arg His Arg Ile Lys Glu His Met Leu Lys Lys
1 5 10 15
31
15
PRT
Artificial Sequence
Description of Artificial Sequence HCMV IE-1
Fragment
31
Arg His Arg Ile Lys Glu His Met Leu Lys Lys Tyr Thr Gln Thr
1 5 10 15
32
15
PRT
Artificial Sequence
Description of Artificial Sequence HCMV IE-1
Fragment
32
Lys Glu His Met Leu Lys Lys Tyr Thr Gln Thr Glu Glu Lys Phe
1 5 10 15
33
15
PRT
Artificial Sequence
Description of Artificial Sequence HCMV IE-1
Fragment
33
Leu Lys Lys Tyr Thr Gln Thr Glu Glu Lys Phe Thr Gly Ala Phe
1 5 10 15
34
15
PRT
Artificial Sequence
Description of Artificial Sequence HCMV IE-1
Fragment
34
Thr Gln Thr Glu Glu Lys Phe Thr Gly Ala Phe Asn Met Met Gly
1 5 10 15
35
15
PRT
Artificial Sequence
Description of Artificial Sequence HCMV IE-1
Fragment
35
Glu Lys Phe Thr Gly Ala Phe Asn Met Met Gly Gly Cys Leu Gln
1 5 10 15
36
15
PRT
Artificial Sequence
Description of Artificial Sequence HCMV IE-1
Fragment
36
Met Asp Pro Asp Asn Pro Asp Glu Gly Pro Ser Ser Lys Val Pro
1 5 10 15
37
15
PRT
Artificial Sequence
Description of Artificial Sequence HCMV IE-1
Fragment
37
Gly Ala Phe Asn Met Met Gly Gly Cys Leu Gln Asn Ala Leu Asp
1 5 10 15
38
15
PRT
Artificial Sequence
Description of Artificial Sequence HCMV IE-1
Fragment
38
Met Met Gly Gly Cys Leu Gln Asn Ala Leu Asp Ile Leu Asp Lys
1 5 10 15
39
15
PRT
Artificial Sequence
Description of Artificial Sequence HCMV IE-1
Fragment
39
Cys Leu Gln Asn Ala Leu Asp Ile Leu Asp Lys Val His Glu Pro
1 5 10 15
40
15
PRT
Artificial Sequence
Description of Artificial Sequence HCMV IE-1
Fragment
40
Ala Leu Asp Ile Leu Asp Lys Val His Glu Pro Phe Glu Glu Met
1 5 10 15
41
15
PRT
Artificial Sequence
Description of Artificial Sequence HCMV IE-1
Fragment
41
Leu Asp Lys Val His Glu Pro Phe Glu Glu Met Lys Cys Ile Gly
1 5 10 15
42
15
PRT
Artificial Sequence
Description of Artificial Sequence HCMV IE-1
Fragment
42
His Glu Pro Phe Glu Glu Met Lys Cys Ile Gly Leu Thr Met Gln
1 5 10 15
43
15
PRT
Artificial Sequence
Description of Artificial Sequence HCMV IE-1
Fragment
43
Glu Glu Met Lys Cys Ile Gly Leu Thr Met Gln Ser Met Tyr Glu
1 5 10 15
44
15
PRT
Artificial Sequence
Description of Artificial Sequence HCMV IE-1
Fragment
44
Cys Ile Gly Leu Thr Met Gln Ser Met Tyr Glu Asn Tyr Ile Val
1 5 10 15
45
15
PRT
Artificial Sequence
Description of Artificial Sequence HCMV IE-1
Fragment
45
Thr Met Gln Ser Met Tyr Glu Asn Tyr Ile Val Pro Glu Asp Lys
1 5 10 15
46
15
PRT
Artificial Sequence
Description of Artificial Sequence HCMV IE-1
Fragment
46
Met Tyr Glu Asn Tyr Ile Val Pro Glu Asp Lys Arg Glu Met Trp
1 5 10 15
47
15
PRT
Artificial Sequence
Description of Artificial Sequence HCMV IE-1
Fragment
47
Asn Pro Asp Glu Gly Pro Ser Ser Lys Val Pro Arg Pro Glu Thr
1 5 10 15
48
15
PRT
Artificial Sequence
Description of Artificial Sequence HCMV IE-1
Fragment
48
Tyr Ile Val Pro Glu Asp Lys Arg Glu Met Trp Met Ala Cys Ile
1 5 10 15
49
15
PRT
Artificial Sequence
Description of Artificial Sequence HCMV IE-1
Fragment
49
Glu Asp Lys Arg Glu Met Trp Met Ala Cys Ile Lys Glu Leu His
1 5 10 15
50
15
PRT
Artificial Sequence
Description of Artificial Sequence HCMV IE-1
Fragment
50
Glu Met Trp Met Ala Cys Ile Lys Glu Leu His Asp Val Ser Lys
1 5 10 15
51
15
PRT
Artificial Sequence
Description of Artificial Sequence HCMV IE-1
Fragment
51
Ala Cys Ile Lys Glu Leu His Asp Val Ser Lys Gly Ala Ala Asn
1 5 10 15
52
15
PRT
Artificial Sequence
Description of Artificial Sequence HCMV IE-1
Fragment
52
Glu Leu His Asp Val Ser Lys Gly Ala Ala Asn Lys Leu Gly Gly
1 5 10 15
53
15
PRT
Artificial Sequence
Description of Artificial Sequence HCMV IE-1
Fragment
53
Val Ser Lys Gly Ala Ala Asn Lys Leu Gly Gly Ala Leu Gln Ala
1 5 10 15
54
15
PRT
Artificial Sequence
Description of Artificial Sequence HCMV IE-1
Fragment
54
Ala Ala Asn Lys Leu Gly Gly Ala Leu Gln Ala Lys Ala Arg Ala
1 5 10 15
55
15
PRT
Artificial Sequence
Description of Artificial Sequence HCMV IE-1
Fragment
55
Leu Gly Gly Ala Leu Gln Ala Lys Ala Arg Ala Lys Lys Asp Glu
1 5 10 15
56
15
PRT
Artificial Sequence
Description of Artificial Sequence HCMV IE-1
Fragment
56
Leu Gln Ala Lys Ala Arg Ala Lys Lys Asp Glu Leu Arg Arg Lys
1 5 10 15
57
15
PRT
Artificial Sequence
Description of Artificial Sequence HCMV IE-1
Fragment
57
Ala Arg Ala Lys Lys Asp Glu Leu Arg Arg Lys Met Met Tyr Met
1 5 10 15
58
15
PRT
Artificial Sequence
Description of Artificial Sequence HCMV IE-1
Fragment
58
Gly Pro Ser Ser Lys Val Pro Arg Pro Glu Thr Pro Val Thr Lys
1 5 10 15
59
15
PRT
Artificial Sequence
Description of Artificial Sequence HCMV IE-1
Fragment
59
Lys Asp Glu Leu Arg Arg Lys Met Met Tyr Met Cys Tyr Arg Asn
1 5 10 15
60
15
PRT
Artificial Sequence
Description of Artificial Sequence HCMV IE-1
Fragment
60
Arg Arg Lys Met Met Tyr Met Cys Tyr Arg Asn Ile Glu Phe Phe
1 5 10 15
61
15
PRT
Artificial Sequence
Description of Artificial Sequence HCMV IE-1
Fragment
61
Met Tyr Met Cys Tyr Arg Asn Ile Glu Phe Phe Thr Lys Asn Ser
1 5 10 15
62
15
PRT
Artificial Sequence
Description of Artificial Sequence HCMV IE-1
Fragment
62
Tyr Arg Asn Ile Glu Phe Phe Thr Lys Asn Ser Ala Phe Pro Lys
1 5 10 15
63
15
PRT
Artificial Sequence
Description of Artificial Sequence HCMV IE-1
Fragment
63
Glu Phe Phe Thr Lys Asn Ser Ala Phe Pro Lys Thr Thr Asn Gly
1 5 10 15
64
15
PRT
Artificial Sequence
Description of Artificial Sequence HCMV IE-1
Fragment
64
Lys Asn Ser Ala Phe Pro Lys Thr Thr Asn Gly Cys Ser Gln Ala
1 5 10 15
65
15
PRT
Artificial Sequence
Description of Artificial Sequence HCMV IE-1
Fragment
65
Phe Pro Lys Thr Thr Asn Gly Cys Ser Gln Ala Met Ala Ala Leu
1 5 10 15
66
15
PRT
Artificial Sequence
Description of Artificial Sequence HCMV IE-1
Fragment
66
Thr Asn Gly Cys Ser Gln Ala Met Ala Ala Leu Gln Asn Leu Pro
1 5 10 15
67
15
PRT
Artificial Sequence
Description of Artificial Sequence HCMV IE-1
Fragment
67
Ser Gln Ala Met Ala Ala Leu Gln Asn Leu Pro Gln Cys Ser Pro
1 5 10 15
68
15
PRT
Artificial Sequence
Description of Artificial Sequence HCMV IE-1
Fragment
68
Ala Ala Leu Gln Asn Leu Pro Gln Cys Ser Pro Asp Glu Ile Met
1 5 10 15
69
15
PRT
Artificial Sequence
Description of Artificial Sequence HCMV IE-1
Fragment
69
Lys Val Pro Arg Pro Glu Thr Pro Val Thr Lys Ala Thr Thr Phe
1 5 10 15
70
15
PRT
Artificial Sequence
Description of Artificial Sequence HCMV IE-1
Fragment
70
Asn Leu Pro Gln Cys Ser Pro Asp Glu Ile Met Ala Tyr Ala Gln
1 5 10 15
71
15
PRT
Artificial Sequence
Description of Artificial Sequence HCMV IE-1
Fragment
71
Cys Ser Pro Asp Glu Ile Met Ala Tyr Ala Gln Lys Ile Phe Lys
1 5 10 15
72
15
PRT
Artificial Sequence
Description of Artificial Sequence HCMV IE-1
Fragment
72
Glu Ile Met Ala Tyr Ala Gln Lys Ile Phe Lys Ile Leu Asp Glu
1 5 10 15
73
15
PRT
Artificial Sequence
Description of Artificial Sequence HCMV IE-1
Fragment
73
Tyr Ala Gln Lys Ile Phe Lys Ile Leu Asp Glu Glu Arg Asp Lys
1 5 10 15
74
15
PRT
Artificial Sequence
Description of Artificial Sequence HCMV IE-1
Fragment
74
Ile Phe Lys Ile Leu Asp Glu Glu Arg Asp Lys Val Leu Thr His
1 5 10 15
75
15
PRT
Artificial Sequence
Description of Artificial Sequence HCMV IE-1
Fragment
75
Leu Asp Glu Glu Arg Asp Lys Val Leu Thr His Ile Asp His Ile
1 5 10 15
76
15
PRT
Artificial Sequence
Description of Artificial Sequence HCMV IE-1
Fragment
76
Arg Asp Lys Val Leu Thr His Ile Asp His Ile Phe Met Asp Ile
1 5 10 15
77
15
PRT
Artificial Sequence
Description of Artificial Sequence HCMV IE-1
Fragment
77
Leu Thr His Ile Asp His Ile Phe Met Asp Ile Leu Thr Thr Cys
1 5 10 15
78
15
PRT
Artificial Sequence
Description of Artificial Sequence HCMV IE-1
Fragment
78
Asp His Ile Phe Met Asp Ile Leu Thr Thr Cys Val Glu Thr Met
1 5 10 15
79
15
PRT
Artificial Sequence
Description of Artificial Sequence HCMV IE-1
Fragment
79
Met Asp Ile Leu Thr Thr Cys Val Glu Thr Met Cys Asn Glu Tyr
1 5 10 15
80
15
PRT
Artificial Sequence
Description of Artificial Sequence HCMV IE-1
Fragment
80
Pro Glu Thr Pro Val Thr Lys Ala Thr Thr Phe Leu Gln Thr Met
1 5 10 15
81
15
PRT
Artificial Sequence
Description of Artificial Sequence HCMV IE-1
Fragment
81
Thr Thr Cys Val Glu Thr Met Cys Asn Glu Tyr Lys Val Thr Ser
1 5 10 15
82
15
PRT
Artificial Sequence
Description of Artificial Sequence HCMV IE-1
Fragment
82
Glu Thr Met Cys Asn Glu Tyr Lys Val Thr Ser Asp Ala Cys Met
1 5 10 15
83
15
PRT
Artificial Sequence
Description of Artificial Sequence HCMV IE-1
Fragment
83
Asn Glu Tyr Lys Val Thr Ser Asp Ala Cys Met Met Thr Met Tyr
1 5 10 15
84
15
PRT
Artificial Sequence
Description of Artificial Sequence HCMV IE-1
Fragment
84
Val Thr Ser Asp Ala Cys Met Met Thr Met Tyr Gly Gly Ile Ser
1 5 10 15
85
15
PRT
Artificial Sequence
Description of Artificial Sequence HCMV IE-1
Fragment
85
Ala Cys Met Met Thr Met Tyr Gly Gly Ile Ser Leu Leu Ser Glu
1 5 10 15
86
15
PRT
Artificial Sequence
Description of Artificial Sequence HCMV IE-1
Fragment
86
Thr Met Tyr Gly Gly Ile Ser Leu Leu Ser Glu Phe Cys Arg Val
1 5 10 15
87
15
PRT
Artificial Sequence
Description of Artificial Sequence HCMV IE-1
Fragment
87
Gly Ile Ser Leu Leu Ser Glu Phe Cys Arg Val Leu Cys Cys Tyr
1 5 10 15
88
15
PRT
Artificial Sequence
Description of Artificial Sequence HCMV IE-1
Fragment
88
Leu Ser Glu Phe Cys Arg Val Leu Cys Cys Tyr Val Leu Glu Glu
1 5 10 15
89
15
PRT
Artificial Sequence
Description of Artificial Sequence HCMV IE-1
Fragment
89
Cys Arg Val Leu Cys Cys Tyr Val Leu Glu Glu Thr Ser Val Met
1 5 10 15
90
15
PRT
Artificial Sequence
Description of Artificial Sequence HCMV IE-1
Fragment
90
Cys Cys Tyr Val Leu Glu Glu Thr Ser Val Met Leu Ala Lys Arg
1 5 10 15
91
15
PRT
Artificial Sequence
Description of Artificial Sequence HCMV IE-1
Fragment
91
Val Thr Lys Ala Thr Thr Phe Leu Gln Thr Met Leu Arg Lys Glu
1 5 10 15
92
15
PRT
Artificial Sequence
Description of Artificial Sequence HCMV IE-1
Fragment
92
Leu Glu Glu Thr Ser Val Met Leu Ala Lys Arg Pro Leu Ile Thr
1 5 10 15
93
15
PRT
Artificial Sequence
Description of Artificial Sequence HCMV IE-1
Fragment
93
Ser Val Met Leu Ala Lys Arg Pro Leu Ile Thr Lys Pro Glu Val
1 5 10 15
94
15
PRT
Artificial Sequence
Description of Artificial Sequence HCMV IE-1
Fragment
94
Ala Lys Arg Pro Leu Ile Thr Lys Pro Glu Val Ile Ser Val Met
1 5 10 15
95
15
PRT
Artificial Sequence
Description of Artificial Sequence HCMV IE-1
Fragment
95
Leu Ile Thr Lys Pro Glu Val Ile Ser Val Met Lys Arg Arg Ile
1 5 10 15
96
15
PRT
Artificial Sequence
Description of Artificial Sequence HCMV IE-1
Fragment
96
Pro Glu Val Ile Ser Val Met Lys Arg Arg Ile Glu Glu Ile Cys
1 5 10 15
97
15
PRT
Artificial Sequence
Description of Artificial Sequence HCMV IE-1
Fragment
97
Ser Val Met Lys Arg Arg Ile Glu Glu Ile Cys Met Lys Val Phe
1 5 10 15
98
15
PRT
Artificial Sequence
Description of Artificial Sequence HCMV IE-1
Fragment
98
Arg Arg Ile Glu Glu Ile Cys Met Lys Val Phe Ala Gln Tyr Ile
1 5 10 15
99
15
PRT
Artificial Sequence
Description of Artificial Sequence HCMV IE-1
Fragment
99
Glu Ile Cys Met Lys Val Phe Ala Gln Tyr Ile Leu Gly Ala Asp
1 5 10 15
100
15
PRT
Artificial Sequence
Description of Artificial Sequence HCMV IE-1
Fragment
100
Lys Val Phe Ala Gln Tyr Ile Leu Gly Ala Asp Pro Leu Arg Val
1 5 10 15
101
15
PRT
Artificial Sequence
Description of Artificial Sequence HCMV IE-1
Fragment
101
Gln Tyr Ile Leu Gly Ala Asp Pro Leu Arg Val Cys Ser Pro Ser
1 5 10 15
102
15
PRT
Artificial Sequence
Description of Artificial Sequence HCMV IE-1
Fragment
102
Thr Thr Phe Leu Gln Thr Met Leu Arg Lys Glu Val Asn Ser Gln
1 5 10 15
103
15
PRT
Artificial Sequence
Description of Artificial Sequence HCMV IE-1
Fragment
103
Gly Ala Asp Pro Leu Arg Val Cys Ser Pro Ser Val Asp Asp Leu
1 5 10 15
104
15
PRT
Artificial Sequence
Description of Artificial Sequence HCMV IE-1
Fragment
104
Leu Arg Val Cys Ser Pro Ser Val Asp Asp Leu Arg Ala Ile Ala
1 5 10 15
105
15
PRT
Artificial Sequence
Description of Artificial Sequence HCMV IE-1
Fragment
105
Ser Pro Ser Val Asp Asp Leu Arg Ala Ile Ala Glu Glu Ser Asp
1 5 10 15
106
15
PRT
Artificial Sequence
Description of Artificial Sequence HCMV IE-1
Fragment
106
Asp Asp Leu Arg Ala Ile Ala Glu Glu Ser Asp Glu Glu Glu Ala
1 5 10 15
107
15
PRT
Artificial Sequence
Description of Artificial Sequence HCMV IE-1
Fragment
107
Ala Ile Ala Glu Glu Ser Asp Glu Glu Glu Ala Ile Val Ala Tyr
1 5 10 15
108
15
PRT
Artificial Sequence
Description of Artificial Sequence HCMV IE-1
Fragment
108
Glu Ser Asp Glu Glu Glu Ala Ile Val Ala Tyr Thr Leu Ala Thr
1 5 10 15
109
15
PRT
Artificial Sequence
Description of Artificial Sequence HCMV IE-1
Fragment
109
Glu Glu Ala Ile Val Ala Tyr Thr Leu Ala Thr Ala Gly Val Ser
1 5 10 15
110
15
PRT
Artificial Sequence
Description of Artificial Sequence HCMV IE-1
Fragment
110
Val Ala Tyr Thr Leu Ala Thr Ala Gly Val Ser Ser Ser Asp Ser
1 5 10 15
111
15
PRT
Artificial Sequence
Description of Artificial Sequence HCMV IE-1
Fragment
111
Leu Ala Thr Ala Gly Val Ser Ser Ser Asp Ser Leu Val Ser Pro
1 5 10 15
112
15
PRT
Artificial Sequence
Description of Artificial Sequence HCMV IE-1
Fragment
112
Gly Val Ser Ser Ser Asp Ser Leu Val Ser Pro Pro Glu Ser Pro
1 5 10 15
113
15
PRT
Artificial Sequence
Description of Artificial Sequence HCMV IE-1
Fragment
113
Glu Glu Arg Glu Asp Thr Val Ser Val Lys Ser Glu Pro Val Ser
1 5 10 15
114
15
PRT
Artificial Sequence
Description of Artificial Sequence HCMV IE-1
Fragment
114
Asp Thr Val Ser Val Lys Ser Glu Pro Val Ser Glu Ile Glu Glu
1 5 10 15
115
15
PRT
Artificial Sequence
Description of Artificial Sequence HCMV IE-1
Fragment
115
Val Lys Ser Glu Pro Val Ser Glu Ile Glu Glu Val Ala Pro Glu
1 5 10 15
116
15
PRT
Artificial Sequence
Description of Artificial Sequence HCMV IE-1
Fragment
116
Pro Val Ser Glu Ile Glu Glu Val Ala Pro Glu Glu Glu Glu Asp
1 5 10 15
117
15
PRT
Artificial Sequence
Description of Artificial Sequence HCMV IE-1
Fragment
117
Ile Glu Glu Val Ala Pro Glu Glu Glu Glu Asp Gly Ala Glu Glu
1 5 10 15
118
15
PRT
Artificial Sequence
Description of Artificial Sequence HCMV IE-1
Fragment
118
Ala Pro Glu Glu Glu Glu Asp Gly Ala Glu Glu Pro Thr Ala Ser
1 5 10 15
119
15
PRT
Artificial Sequence
Description of Artificial Sequence HCMV IE-1
Fragment
119
Glu Glu Asp Gly Ala Glu Glu Pro Thr Ala Ser Gly Gly Lys Ser
1 5 10 15
120
15
PRT
Artificial Sequence
Description of Artificial Sequence HCMV IE-1
Fragment
120
Ala Glu Glu Pro Thr Ala Ser Gly Gly Lys Ser Thr His Pro Met
1 5 10 15
121
15
PRT
Artificial Sequence
Description of Artificial Sequence HCMV IE-1
Fragment
121
Thr Ala Ser Gly Gly Lys Ser Thr His Pro Met Val Thr Arg Ser
1 5 10 15
122
15
PRT
Artificial Sequence
Description of Artificial Sequence HCMV IE-1
Fragment
122
Gly Lys Ser Thr His Pro Met Val Thr Arg Ser Lys Ala Asp Gln
1 5 10 15
123
15
PRT
Artificial Sequence
Description of Artificial Sequence HCMV pp65
Fragment
123
Met Glu Ser Arg Gly Arg Arg Cys Pro Glu Met Ile Ser Val Leu
1 5 10 15
124
15
PRT
Artificial Sequence
Description of Artificial Sequence HCMV pp65
Fragment
124
His Glu Thr Arg Leu Leu Gln Thr Gly Ile His Val Arg Val Ser
1 5 10 15
125
15
PRT
Artificial Sequence
Description of Artificial Sequence HCMV pp65
Fragment
125
Asp Asp Val Trp Thr Ser Gly Ser Asp Ser Asp Glu Glu Leu Val
1 5 10 15
126
15
PRT
Artificial Sequence
Description of Artificial Sequence HCMV pp65
Fragment
126
Thr Ser Gly Ser Asp Ser Asp Glu Glu Leu Val Thr Thr Glu Arg
1 5 10 15
127
15
PRT
Artificial Sequence
Description of Artificial Sequence HCMV pp65
Fragment
127
Asp Ser Asp Glu Glu Leu Val Thr Thr Glu Arg Lys Thr Pro Arg
1 5 10 15
128
15
PRT
Artificial Sequence
Description of Artificial Sequence HCMV pp65
Fragment
128
Glu Leu Val Thr Thr Glu Arg Lys Thr Pro Arg Val Thr Gly Gly
1 5 10 15
129
15
PRT
Artificial Sequence
Description of Artificial Sequence HCMV pp65
Fragment
129
Thr Glu Arg Lys Thr Pro Arg Val Thr Gly Gly Gly Ala Met Ala
1 5 10 15
130
15
PRT
Artificial Sequence
Description of Artificial Sequence HCMV pp65
Fragment
130
Thr Pro Arg Val Thr Gly Gly Gly Ala Met Ala Gly Ala Ser Thr
1 5 10 15
131
15
PRT
Artificial Sequence
Description of Artificial Sequence HCMV pp65
Fragment
131
Thr Gly Gly Gly Ala Met Ala Gly Ala Ser Thr Ser Ala Gly Arg
1 5 10 15
132
15
PRT
Artificial Sequence
Description of Artificial Sequence HCMV pp65
Fragment
132
Ala Met Ala Gly Ala Ser Thr Ser Ala Gly Arg Lys Arg Lys Ser
1 5 10 15
133
15
PRT
Artificial Sequence
Description of Artificial Sequence HCMV pp65
Fragment
133
Ala Ser Thr Ser Ala Gly Arg Lys Arg Lys Ser Ala Ser Ser Ala
1 5 10 15
134
15
PRT
Artificial Sequence
Description of Artificial Sequence HCMV pp65
Fragment
134
Ala Gly Arg Lys Arg Lys Ser Ala Ser Ser Ala Thr Ala Cys Thr
1 5 10 15
135
15
PRT
Artificial Sequence
Description of Artificial Sequence HCMV pp65
Fragment
135
Leu Leu Gln Thr Gly Ile His Val Arg Val Ser Gln Pro Ser Leu
1 5 10 15
136
15
PRT
Artificial Sequence
Description of Artificial Sequence HCMV pp65
Fragment
136
Arg Lys Ser Ala Ser Ser Ala Thr Ala Cys Thr Ser Gly Val Met
1 5 10 15
137
15
PRT
Artificial Sequence
Description of Artificial Sequence HCMV pp65
Fragment
137
Ser Ser Ala Thr Ala Cys Thr Ser Gly Val Met Thr Arg Gly Arg
1 5 10 15
138
15
PRT
Artificial Sequence
Description of Artificial Sequence HCMV pp65
Fragment
138
Gly Ile His Val Arg Val Ser Gln Pro Ser Leu Ile Leu Val Ser
1 5 10 15
139
15
PRT
Artificial Sequence
Description of Artificial Sequence HCMV pp65
Fragment
139
Arg Val Ser Gln Pro Ser Leu Ile Leu Val Ser Gln Tyr Thr Pro
1 5 10 15
140
15
PRT
Artificial Sequence
Description of Artificial Sequence HCMV pp65
Fragment
140
Pro Ser Leu Ile Leu Val Ser Gln Tyr Thr Pro Asp Ser Thr Pro
1 5 10 15
141
15
PRT
Artificial Sequence
Description of Artificial Sequence HCMV pp65
Fragment
141
Leu Val Ser Gln Tyr Thr Pro Asp Ser Thr Pro Cys His Arg Gly
1 5 10 15
142
15
PRT
Artificial Sequence
Description of Artificial Sequence HCMV pp65
Fragment
142
Tyr Thr Pro Asp Ser Thr Pro Cys His Arg Gly Asp Asn Gln Leu
1 5 10 15
143
15
PRT
Artificial Sequence
Description of Artificial Sequence HCMV pp65
Fragment
143
Ser Thr Pro Cys His Arg Gly Asp Asn Gln Leu Gln Val Gln His
1 5 10 15
144
15
PRT
Artificial Sequence
Description of Artificial Sequence HCMV pp65
Fragment
144
His Arg Gly Asp Asn Gln Leu Gln Val Gln His Thr Tyr Phe Thr
1 5 10 15
145
15
PRT
Artificial Sequence
Description of Artificial Sequence HCMV pp65
Fragment
145
Asn Gln Leu Gln Val Gln His Thr Tyr Phe Thr Gly Ser Glu Val
1 5 10 15
146
15
PRT
Artificial Sequence
Description of Artificial Sequence HCMV pp65
Fragment
146
Gly Arg Arg Cys Pro Glu Met Ile Ser Val Leu Gly Pro Ile Ser
1 5 10 15
147
15
PRT
Artificial Sequence
Description of Artificial Sequence HCMV pp65
Fragment
147
Val Gln His Thr Tyr Phe Thr Gly Ser Glu Val Glu Asn Val Ser
1 5 10 15
148
15
PRT
Artificial Sequence
Description of Artificial Sequence HCMV pp65
Fragment
148
Tyr Phe Thr Gly Ser Glu Val Glu Asn Val Ser Val Asn Val His
1 5 10 15
149
15
PRT
Artificial Sequence
Description of Artificial Sequence HCMV pp65
Fragment
149
Ser Glu Val Glu Asn Val Ser Val Asn Val His Asn Pro Thr Gly
1 5 10 15
150
15
PRT
Artificial Sequence
Description of Artificial Sequence HCMV pp65
Fragment
150
Asn Val Ser Val Asn Val His Asn Pro Thr Gly Arg Ser Ile Cys
1 5 10 15
151
15
PRT
Artificial Sequence
Description of Artificial Sequence HCMV pp65
Fragment
151
Asn Val His Asn Pro Thr Gly Arg Ser Ile Cys Pro Ser Gln Glu
1 5 10 15
152
15
PRT
Artificial Sequence
Description of Artificial Sequence HCMV pp65
Fragment
152
Pro Thr Gly Arg Ser Ile Cys Pro Ser Gln Glu Pro Met Ser Ile
1 5 10 15
153
15
PRT
Artificial Sequence
Description of Artificial Sequence HCMV pp65
Fragment
153
Ser Ile Cys Pro Ser Gln Glu Pro Met Ser Ile Tyr Val Tyr Ala
1 5 10 15
154
15
PRT
Artificial Sequence
Description of Artificial Sequence HCMV pp65
Fragment
154
Ser Gln Glu Pro Met Ser Ile Tyr Val Tyr Ala Leu Pro Leu Lys
1 5 10 15
155
15
PRT
Artificial Sequence
Description of Artificial Sequence HCMV pp65
Fragment
155
Met Ser Ile Tyr Val Tyr Ala Leu Pro Leu Lys Met Leu Asn Ile
1 5 10 15
156
15
PRT
Artificial Sequence
Description of Artificial Sequence HCMV pp65
Fragment
156
Val Tyr Ala Leu Pro Leu Lys Met Leu Asn Ile Pro Ser Ile Asn
1 5 10 15
157
15
PRT
Artificial Sequence
Description of Artificial Sequence HCMV pp65
Fragment
157
Pro Glu Met Ile Ser Val Leu Gly Pro Ile Ser Gly His Val Leu
1 5 10 15
158
15
PRT
Artificial Sequence
Description of Artificial Sequence HCMV pp65
Fragment
158
Pro Leu Lys Met Leu Asn Ile Pro Ser Ile Asn Val His His Tyr
1 5 10 15
159
15
PRT
Artificial Sequence
Description of Artificial Sequence HCMV pp65
Fragment
159
Leu Asn Ile Pro Ser Ile Asn Val His His Tyr Pro Ser Ala Ala
1 5 10 15
160
15
PRT
Artificial Sequence
Description of Artificial Sequence HCMV pp65
Fragment
160
Ser Ile Asn Val His His Tyr Pro Ser Ala Ala Glu Arg Lys His
1 5 10 15
161
15
PRT
Artificial Sequence
Description of Artificial Sequence HCMV pp65
Fragment
161
His His Tyr Pro Ser Ala Ala Glu Arg Lys His Arg His Leu Pro
1 5 10 15
162
15
PRT
Artificial Sequence
Description of Artificial Sequence HCMV pp65
Fragment
162
Ser Ala Ala Glu Arg Lys His Arg His Leu Pro Val Ala Asp Ala
1 5 10 15
163
15
PRT
Artificial Sequence
Description of Artificial Sequence HCMV pp65
Fragment
163
Arg Lys His Arg His Leu Pro Val Ala Asp Ala Val Ile His Ala
1 5 10 15
164
15
PRT
Artificial Sequence
Description of Artificial Sequence HCMV pp65
Fragment
164
His Leu Pro Val Ala Asp Ala Val Ile His Ala Ser Gly Lys Gln
1 5 10 15
165
15
PRT
Artificial Sequence
Description of Artificial Sequence HCMV pp65
Fragment
165
Ala Asp Ala Val Ile His Ala Ser Gly Lys Gln Met Trp Gln Ala
1 5 10 15
166
15
PRT
Artificial Sequence
Description of Artificial Sequence HCMV pp65
Fragment
166
Ile His Ala Ser Gly Lys Gln Met Trp Gln Ala Arg Leu Thr Val
1 5 10 15
167
15
PRT
Artificial Sequence
Description of Artificial Sequence HCMV pp65
Fragment
167
Gly Lys Gln Met Trp Gln Ala Arg Leu Thr Val Ser Gly Leu Ala
1 5 10 15
168
15
PRT
Artificial Sequence
Description of Artificial Sequence HCMV pp65
Fragment
168
Ser Val Leu Gly Pro Ile Ser Gly His Val Leu Lys Ala Val Phe
1 5 10 15
169
15
PRT
Artificial Sequence
Description of Artificial Sequence HCMV pp65
Fragment
169
Trp Gln Ala Arg Leu Thr Val Ser Gly Leu Ala Trp Thr Arg Gln
1 5 10 15
170
15
PRT
Artificial Sequence
Description of Artificial Sequence HCMV pp65
Fragment
170
Leu Thr Val Ser Gly Leu Ala Trp Thr Arg Gln Gln Asn Gln Trp
1 5 10 15
171
15
PRT
Artificial Sequence
Description of Artificial Sequence HCMV pp65
Fragment
171
Gly Leu Ala Trp Thr Arg Gln Gln Asn Gln Trp Lys Glu Pro Asp
1 5 10 15
172
15
PRT
Artificial Sequence
Description of Artificial Sequence HCMV pp65
Fragment
172
Thr Arg Gln Gln Asn Gln Trp Lys Glu Pro Asp Val Tyr Tyr Thr
1 5 10 15
173
15
PRT
Artificial Sequence
Description of Artificial Sequence HCMV pp65
Fragment
173
Asn Gln Trp Lys Glu Pro Asp Val Tyr Tyr Thr Ser Ala Phe Val
1 5 10 15
174
15
PRT
Artificial Sequence
Description of Artificial Sequence HCMV pp65
Fragment
174
Glu Pro Asp Val Tyr Tyr Thr Ser Ala Phe Val Phe Pro Thr Lys
1 5 10 15
175
15
PRT
Artificial Sequence
Description of Artificial Sequence HCMV pp65
Fragment
175
Tyr Tyr Thr Ser Ala Phe Val Phe Pro Thr Lys Asp Val Ala Leu
1 5 10 15
176
15
PRT
Artificial Sequence
Description of Artificial Sequence HCMV pp65
Fragment
176
Ala Phe Val Phe Pro Thr Lys Asp Val Ala Leu Arg His Val Val
1 5 10 15
177
15
PRT
Artificial Sequence
Description of Artificial Sequence HCMV pp65
Fragment
177
Pro Thr Lys Asp Val Ala Leu Arg His Val Val Cys Ala His Glu
1 5 10 15
178
15
PRT
Artificial Sequence
Description of Artificial Sequence HCMV pp65
Fragment
178
Val Ala Leu Arg His Val Val Cys Ala His Glu Leu Val Cys Ser
1 5 10 15
179
15
PRT
Artificial Sequence
Description of Artificial Sequence HCMV pp65
Fragment
179
Pro Ile Ser Gly His Val Leu Lys Ala Val Phe Ser Arg Gly Asp
1 5 10 15
180
15
PRT
Artificial Sequence
Description of Artificial Sequence HCMV pp65
Fragment
180
His Val Val Cys Ala His Glu Leu Val Cys Ser Met Glu Asn Thr
1 5 10 15
181
15
PRT
Artificial Sequence
Description of Artificial Sequence HCMV pp65
Fragment
181
Ala His Glu Leu Val Cys Ser Met Glu Asn Thr Arg Ala Thr Lys
1 5 10 15
182
15
PRT
Artificial Sequence
Description of Artificial Sequence HCMV pp65
Fragment
182
Val Cys Ser Met Glu Asn Thr Arg Ala Thr Lys Met Gln Val Ile
1 5 10 15
183
15
PRT
Artificial Sequence
Description of Artificial Sequence HCMV pp65
Fragment
183
Glu Asn Thr Arg Ala Thr Lys Met Gln Val Ile Gly Asp Gln Tyr
1 5 10 15
184
15
PRT
Artificial Sequence
Description of Artificial Sequence HCMV pp65
Fragment
184
Ala Thr Lys Met Gln Val Ile Gly Asp Gln Tyr Val Lys Val Tyr
1 5 10 15
185
15
PRT
Artificial Sequence
Description of Artificial Sequence HCMV pp65
Fragment
185
Gln Val Ile Gly Asp Gln Tyr Val Lys Val Tyr Leu Glu Ser Phe
1 5 10 15
186
15
PRT
Artificial Sequence
Description of Artificial Sequence HCMV pp65
Fragment
186
Asp Gln Tyr Val Lys Val Tyr Leu Glu Ser Phe Cys Glu Asp Val
1 5 10 15
187
15
PRT
Artificial Sequence
Description of Artificial Sequence HCMV pp65
Fragment
187
Lys Val Tyr Leu Glu Ser Phe Cys Glu Asp Val Pro Ser Gly Lys
1 5 10 15
188
15
PRT
Artificial Sequence
Description of Artificial Sequence HCMV pp65
Fragment
188
Glu Ser Phe Cys Glu Asp Val Pro Ser Gly Lys Leu Phe Met His
1 5 10 15
189
15
PRT
Artificial Sequence
Description of Artificial Sequence HCMV pp65
Fragment
189
Glu Asp Val Pro Ser Gly Lys Leu Phe Met His Val Thr Leu Gly
1 5 10 15
190
15
PRT
Artificial Sequence
Description of Artificial Sequence HCMV pp65
Fragment
190
His Val Leu Lys Ala Val Phe Ser Arg Gly Asp Thr Pro Val Leu
1 5 10 15
191
15
PRT
Artificial Sequence
Description of Artificial Sequence HCMV pp65
Fragment
191
Ser Gly Lys Leu Phe Met His Val Thr Leu Gly Ser Asp Val Glu
1 5 10 15
192
15
PRT
Artificial Sequence
Description of Artificial Sequence HCMV pp65
Fragment
192
Phe Met His Val Thr Leu Gly Ser Asp Val Glu Glu Asp Leu Thr
1 5 10 15
193
15
PRT
Artificial Sequence
Description of Artificial Sequence HCMV pp65
Fragment
193
Thr Leu Gly Ser Asp Val Glu Glu Asp Leu Thr Met Thr Arg Asn
1 5 10 15
194
15
PRT
Artificial Sequence
Description of Artificial Sequence HCMV pp65
Fragment
194
Asp Val Glu Glu Asp Leu Thr Met Thr Arg Asn Pro Gln Pro Phe
1 5 10 15
195
15
PRT
Artificial Sequence
Description of Artificial Sequence HCMV pp65
Fragment
195
Asp Leu Thr Met Thr Arg Asn Pro Gln Pro Phe Met Arg Pro His
1 5 10 15
196
15
PRT
Artificial Sequence
Description of Artificial Sequence HCMV pp65
Fragment
196
Thr Arg Asn Pro Gln Pro Phe Met Arg Pro His Glu Arg Asn Gly
1 5 10 15
197
15
PRT
Artificial Sequence
Description of Artificial Sequence HCMV pp65
Fragment
197
Gln Pro Phe Met Arg Pro His Glu Arg Asn Gly Phe Thr Val Leu
1 5 10 15
198
15
PRT
Artificial Sequence
Description of Artificial Sequence HCMV pp65
Fragment
198
Arg Pro His Glu Arg Asn Gly Phe Thr Val Leu Cys Pro Lys Asn
1 5 10 15
199
15
PRT
Artificial Sequence
Description of Artificial Sequence HCMV pp65
Fragment
199
Arg Asn Gly Phe Thr Val Leu Cys Pro Lys Asn Met Ile Ile Lys
1 5 10 15
200
15
PRT
Artificial Sequence
Description of Artificial Sequence HCMV pp65
Fragment
200
Thr Val Leu Cys Pro Lys Asn Met Ile Ile Lys Pro Gly Lys Ile
1 5 10 15
201
15
PRT
Artificial Sequence
Description of Artificial Sequence HCMV pp65
Fragment
201
Ala Val Phe Ser Arg Gly Asp Thr Pro Val Leu Pro His Glu Thr
1 5 10 15
202
15
PRT
Artificial Sequence
Description of Artificial Sequence HCMV pp65
Fragment
202
Pro Lys Asn Met Ile Ile Lys Pro Gly Lys Ile Ser His Ile Met
1 5 10 15
203
15
PRT
Artificial Sequence
Description of Artificial Sequence HCMV pp65
Fragment
203
Ile Ile Lys Pro Gly Lys Ile Ser His Ile Met Leu Asp Val Ala
1 5 10 15
204
15
PRT
Artificial Sequence
Description of Artificial Sequence HCMV pp65
Fragment
204
Gly Lys Ile Ser His Ile Met Leu Asp Val Ala Phe Thr Ser His
1 5 10 15
205
15
PRT
Artificial Sequence
Description of Artificial Sequence HCMV pp65
Fragment
205
His Ile Met Leu Asp Val Ala Phe Thr Ser His Glu His Phe Gly
1 5 10 15
206
15
PRT
Artificial Sequence
Description of Artificial Sequence HCMV pp65
Fragment
206
Asp Val Ala Phe Thr Ser His Glu His Phe Gly Leu Leu Cys Pro
1 5 10 15
207
15
PRT
Artificial Sequence
Description of Artificial Sequence HCMV pp65
Fragment
207
Thr Ser His Glu His Phe Gly Leu Leu Cys Pro Lys Ser Ile Pro
1 5 10 15
208
15
PRT
Artificial Sequence
Description of Artificial Sequence HCMV pp65
Fragment
208
His Phe Gly Leu Leu Cys Pro Lys Ser Ile Pro Gly Leu Ser Ile
1 5 10 15
209
15
PRT
Artificial Sequence
Description of Artificial Sequence HCMV pp65
Fragment
209
Leu Cys Pro Lys Ser Ile Pro Gly Leu Ser Ile Ser Gly Asn Leu
1 5 10 15
210
15
PRT
Artificial Sequence
Description of Artificial Sequence HCMV pp65
Fragment
210
Ser Ile Pro Gly Leu Ser Ile Ser Gly Asn Leu Leu Met Asn Gly
1 5 10 15
211
15
PRT
Artificial Sequence
Description of Artificial Sequence HCMV pp65
Fragment
211
Leu Ser Ile Ser Gly Asn Leu Leu Met Asn Gly Gln Gln Ile Phe
1 5 10 15
212
15
PRT
Artificial Sequence
Description of Artificial Sequence HCMV pp65
Fragment
212
Arg Gly Asp Thr Pro Val Leu Pro His Glu Thr Arg Leu Leu Gln
1 5 10 15
213
15
PRT
Artificial Sequence
Description of Artificial Sequence HCMV pp65
Fragment
213
Gly Asn Leu Leu Met Asn Gly Gln Gln Ile Phe Leu Glu Val Gln
1 5 10 15
214
15
PRT
Artificial Sequence
Description of Artificial Sequence HCMV pp65
Fragment
214
Met Asn Gly Gln Gln Ile Phe Leu Glu Val Gln Ala Ile Arg Glu
1 5 10 15
215
15
PRT
Artificial Sequence
Description of Artificial Sequence HCMV pp65
Fragment
215
Gln Ile Phe Leu Glu Val Gln Ala Ile Arg Glu Thr Val Glu Leu
1 5 10 15
216
15
PRT
Artificial Sequence
Description of Artificial Sequence HCMV pp65
Fragment
216
Glu Val Gln Ala Ile Arg Glu Thr Val Glu Leu Arg Gln Tyr Asp
1 5 10 15
217
15
PRT
Artificial Sequence
Description of Artificial Sequence HCMV pp65
Fragment
217
Ile Arg Glu Thr Val Glu Leu Arg Gln Tyr Asp Pro Val Ala Ala
1 5 10 15
218
15
PRT
Artificial Sequence
Description of Artificial Sequence HCMV pp65
Fragment
218
Val Glu Leu Arg Gln Tyr Asp Pro Val Ala Ala Leu Phe Phe Phe
1 5 10 15
219
15
PRT
Artificial Sequence
Description of Artificial Sequence HCMV pp65
Fragment
219
Gln Tyr Asp Pro Val Ala Ala Leu Phe Phe Phe Asp Ile Asp Leu
1 5 10 15
220
15
PRT
Artificial Sequence
Description of Artificial Sequence HCMV pp65
Fragment
220
Val Ala Ala Leu Phe Phe Phe Asp Ile Asp Leu Leu Leu Gln Arg
1 5 10 15
221
15
PRT
Artificial Sequence
Description of Artificial Sequence HCMV pp65
Fragment
221
Phe Phe Phe Asp Ile Asp Leu Leu Leu Gln Arg Gly Pro Gln Tyr
1 5 10 15
222
15
PRT
Artificial Sequence
Description of Artificial Sequence HCMV pp65
Fragment
222
Ile Asp Leu Leu Leu Gln Arg Gly Pro Gln Tyr Ser Glu His Pro
1 5 10 15
223
15
PRT
Artificial Sequence
Description of Artificial Sequence HCMV pp65
Fragment
223
Pro Val Leu Pro His Glu Thr Arg Leu Leu Gln Thr Gly Ile His
1 5 10 15
224
15
PRT
Artificial Sequence
Description of Artificial Sequence HCMV pp65
Fragment
224
Leu Gln Arg Gly Pro Gln Tyr Ser Glu His Pro Thr Phe Thr Ser
1 5 10 15
225
15
PRT
Artificial Sequence
Description of Artificial Sequence HCMV pp65
Fragment
225
Pro Gln Tyr Ser Glu His Pro Thr Phe Thr Ser Gln Tyr Arg Ile
1 5 10 15
226
15
PRT
Artificial Sequence
Description of Artificial Sequence HCMV pp65
Fragment
226
Glu His Pro Thr Phe Thr Ser Gln Tyr Arg Ile Gln Gly Lys Leu
1 5 10 15
227
15
PRT
Artificial Sequence
Description of Artificial Sequence HCMV pp65
Fragment
227
Phe Thr Ser Gln Tyr Arg Ile Gln Gly Lys Leu Glu Tyr Arg His
1 5 10 15
228
15
PRT
Artificial Sequence
Description of Artificial Sequence HCMV pp65
Fragment
228
Tyr Arg Ile Gln Gly Lys Leu Glu Tyr Arg His Thr Trp Asp Arg
1 5 10 15
229
15
PRT
Artificial Sequence
Description of Artificial Sequence HCMV pp65
Fragment
229
Gly Lys Leu Glu Tyr Arg His Thr Trp Asp Arg His Asp Glu Gly
1 5 10 15
230
15
PRT
Artificial Sequence
Description of Artificial Sequence HCMV pp65
Fragment
230
Tyr Arg His Thr Trp Asp Arg His Asp Glu Gly Ala Ala Gln Gly
1 5 10 15
231
15
PRT
Artificial Sequence
Description of Artificial Sequence HCMV pp65
Fragment
231
Trp Asp Arg His Asp Glu Gly Ala Ala Gln Gly Asp Asp Asp Val
1 5 10 15
232
15
PRT
Artificial Sequence
Description of Artificial Sequence HCMV pp65
Fragment
232
Asp Glu Gly Ala Ala Gln Gly Asp Asp Asp Val Trp Thr Ser Gly
1 5 10 15
233
15
PRT
Artificial Sequence
Description of Artificial Sequence HCMV pp65
Fragment
233
Ala Gln Gly Asp Asp Asp Val Trp Thr Ser Gly Ser Asp Ser Asp
1 5 10 15
234
15
PRT
Artificial Sequence
Description of Artificial Sequence HCMV pp65
Fragment
234
Ala Cys Thr Ser Gly Val Met Thr Arg Gly Arg Leu Lys Ala Glu
1 5 10 15
235
15
PRT
Artificial Sequence
Description of Artificial Sequence HCMV pp65
Fragment
235
Gly Val Met Thr Arg Gly Arg Leu Lys Ala Glu Ser Thr Val Ala
1 5 10 15
236
15
PRT
Artificial Sequence
Description of Artificial Sequence HCMV pp65
Fragment
236
Arg Gly Arg Leu Lys Ala Glu Ser Thr Val Ala Pro Glu Glu Asp
1 5 10 15
237
15
PRT
Artificial Sequence
Description of Artificial Sequence HCMV pp65
Fragment
237
Lys Ala Glu Ser Thr Val Ala Pro Glu Glu Asp Thr Asp Glu Asp
1 5 10 15
238
15
PRT
Artificial Sequence
Description of Artificial Sequence HCMV pp65
Fragment
238
Thr Val Ala Pro Glu Glu Asp Thr Asp Glu Asp Ser Asp Asn Glu
1 5 10 15
239
15
PRT
Artificial Sequence
Description of Artificial Sequence HCMV pp65
Fragment
239
Glu Glu Asp Thr Asp Glu Asp Ser Asp Asn Glu Ile His Asn Pro
1 5 10 15
240
15
PRT
Artificial Sequence
Description of Artificial Sequence HCMV pp65
Fragment
240
Asp Glu Asp Ser Asp Asn Glu Ile His Asn Pro Ala Val Phe Thr
1 5 10 15
241
15
PRT
Artificial Sequence
Description of Artificial Sequence HCMV pp65
Fragment
241
Asp Asn Glu Ile His Asn Pro Ala Val Phe Thr Trp Pro Pro Trp
1 5 10 15
242
15
PRT
Artificial Sequence
Description of Artificial Sequence HCMV pp65
Fragment
242
His Asn Pro Ala Val Phe Thr Trp Pro Pro Trp Gln Ala Gly Ile
1 5 10 15
243
15
PRT
Artificial Sequence
Description of Artificial Sequence HCMV pp65
Fragment
243
Val Phe Thr Trp Pro Pro Trp Gln Ala Gly Ile Leu Ala Arg Asn
1 5 10 15
244
15
PRT
Artificial Sequence
Description of Artificial Sequence HCMV pp65
Fragment
244
Pro Pro Trp Gln Ala Gly Ile Leu Ala Arg Asn Leu Val Pro Met
1 5 10 15
245
15
PRT
Artificial Sequence
Description of Artificial Sequence HCMV pp65
Fragment
245
Ala Gly Ile Leu Ala Arg Asn Leu Val Pro Met Val Ala Thr Val
1 5 10 15
246
15
PRT
Artificial Sequence
Description of Artificial Sequence HCMV pp65
Fragment
246
Ala Arg Asn Leu Val Pro Met Val Ala Thr Val Gln Gly Gln Asn
1 5 10 15
247
15
PRT
Artificial Sequence
Description of Artificial Sequence HCMV pp65
Fragment
247
Val Pro Met Val Ala Thr Val Gln Gly Gln Asn Leu Lys Tyr Gln
1 5 10 15
248
15
PRT
Artificial Sequence
Description of Artificial Sequence HCMV pp65
Fragment
248
Ala Thr Val Gln Gly Gln Asn Leu Lys Tyr Gln Glu Phe Phe Trp
1 5 10 15
249
15
PRT
Artificial Sequence
Description of Artificial Sequence HCMV pp65
Fragment
249
Gly Gln Asn Leu Lys Tyr Gln Glu Phe Phe Trp Asp Ala Asn Asp
1 5 10 15
250
15
PRT
Artificial Sequence
Description of Artificial Sequence HCMV pp65
Fragment
250
Lys Tyr Gln Glu Phe Phe Trp Asp Ala Asn Asp Ile Tyr Arg Ile
1 5 10 15
251
15
PRT
Artificial Sequence
Description of Artificial Sequence HCMV pp65
Fragment
251
Phe Phe Trp Asp Ala Asn Asp Ile Tyr Arg Ile Phe Ala Glu Leu
1 5 10 15
252
15
PRT
Artificial Sequence
Description of Artificial Sequence HCMV pp65
Fragment
252
Ala Asn Asp Ile Tyr Arg Ile Phe Ala Glu Leu Glu Gly Val Trp
1 5 10 15
253
15
PRT
Artificial Sequence
Description of Artificial Sequence HCMV pp65
Fragment
253
Tyr Arg Ile Phe Ala Glu Leu Glu Gly Val Trp Gln Pro Ala Ala
1 5 10 15
254
15
PRT
Artificial Sequence
Description of Artificial Sequence HCMV pp65
Fragment
254
Ala Glu Leu Glu Gly Val Trp Gln Pro Ala Ala Gln Pro Lys Arg
1 5 10 15
255
15
PRT
Artificial Sequence
Description of Artificial Sequence HCMV pp65
Fragment
255
Gly Val Trp Gln Pro Ala Ala Gln Pro Lys Arg Arg Arg His Arg
1 5 10 15
256
15
PRT
Artificial Sequence
Description of Artificial Sequence HCMV pp65
Fragment
256
Pro Ala Ala Gln Pro Lys Arg Arg Arg His Arg Gln Asp Ala Leu
1 5 10 15
257
15
PRT
Artificial Sequence
Description of Artificial Sequence HCMV pp65
Fragment
257
Pro Lys Arg Arg Arg His Arg Gln Asp Ala Leu Pro Gly Pro Cys
1 5 10 15
258
15
PRT
Artificial Sequence
Description of Artificial Sequence HCMV pp65
Fragment
258
Arg His Arg Gln Asp Ala Leu Pro Gly Pro Cys Ile Ala Ser Thr
1 5 10 15
259
15
PRT
Artificial Sequence
Description of Artificial Sequence HCMV pp65
Fragment
259
Asp Ala Leu Pro Gly Pro Cys Ile Ala Ser Thr Pro Lys Lys His
1 5 10 15
260
15
PRT
Artificial Sequence
Description of Artificial Sequence HCMV pp65
Fragment
260
Leu Pro Gly Pro Cys Ile Ala Ser Thr Pro Lys Lys His Arg Gly
1 5 10 15